Liposomes are microparticulate lipoidal vesicles which are under extensive investigation as
drug carriers for improving the delivery of therapeutic agents. Due to new developments in …

Paclitaxel (Taxol®) is a promising anti-tumor agent with poor water solubility. It is effective for
various cancers especially ovarian and breast cancer. Intravenous administration of a …

The microenvironment is known to critically modulate tumor progression, yet its role in
regulating treatment response is poorly understood. Here we found increased macrophage …

Chemically functionalized single-walled carbon nanotubes (SWNT) have shown promise in
tumor-targeted accumulation in mice and exhibit biocompatibility, excretion, and little toxicity …

Abstract ABI-007, an albumin-bound, 130-nm particle form of paclitaxel, was developed to
avoid Cremophor/ethanol-associated toxicities in Cremophor-based paclitaxel (Taxol) and …

Mitochondrion-orientated transportation of smart liposomes has been developed as a
promising strategy to deliver anticancer drugs directly to tumor sites, and these have a …

Over the past three decades, taxanes represent one of the most important new classes of
drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer …

The main objective of this study was to develop a polymeric drug delivery system for
paclitaxel, intended to be intravenously administered, capable of improving the therapeutic …

Combination strategy involving cyclodextrin (CD) complexation and liposomal system was
investigated for Paclitaxel (PTX) to improve loading. Complexation was done using 2, 6-di-O …

Taxol® is a marketed product for the treatment of ovarian, breast, non-small cell lung cancer
and AIDS-related Kaposi's Sarcoma. It is thus far one of the most effective anticancer drugs …